WASHINGTON — Health and Human Services Secretary Alex Azar called on Congress Friday to upend the way drugs are paid for by “immediately” passing a law banning rebates that drug makers pay to insurers.

His push comes the morning after after HHS announced a policy proposal that would eliminate rebates in the Medicare program, which the department claims will lower the amount of money seniors spend on prescription drugs at the pharmacy. Though HHS estimates it will raise premiums in the program, it believes patients will ultimately save money.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • These PBM’s still have a few tricks up their sleeve . There’s the price spread, DIR fees, Waiting a week to update their computers prices when drugs do go up in price . Then there are all the commercial accounts where none of this comes into play and they can still charge their extortion …. I mean drug rebate fee to be on formulary. Have no fear , PBM’s will always be the MAFIA of the pharma industry !!!!

    • They are an organization underground. But here is why.

      These large PBMs 20 years ago were adjudicators, clinical guidance, and offered direction on financials. In that past twenty years they absorbed the specialty distribution channels handling the massive growth of biological and they took over all contracting for 90% of the nations insurers. The market place basically allowed multiple conflict of interests in healthcare become melded into one huge machine. The relationships that exist in this model are solid as granite and the good old boys will fight hard to not allow it to broken down. Transparency, routine audits, and reform watch dogs is a must. You don’t know where you can help the healthcare cost issue until you break down the silos that are thick in walls. Separation of these multiple functions inside the current PBM model is a must. Them once separate they should be monitored and evaluated separately.

  • So the PBMs will sue. Do they realize the can of worms they open when their business practices get laid bare in court (i.e., what % they pocketed vs. passing on to the patient)? That would not end well for them.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy